Oman Journal of Ophthalmology

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 12  |  Issue : 2  |  Page : 99--103

Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration


Thomas Siempis, Mariam El Abiary, Radhika Patel, Manish Gupta 
 Department of Ophthalmology, Tennent Institute of Ophthalmology, Glasgow, Scotland, UK

Correspondence Address:
Dr. Thomas Siempis
Stobhill Hospital, 133 Balornock Rood, Glasgow, G21 3UW, Scotland
UK

BACKGROUND: Aflibercept is widely used as a treatment for neovascular age-related macular degeneration (nAMD). Nevertheless, there is no consensus in the optimal injection frequency in the 2nd year of treatment along with little real-world data on visual outcomes. On that basis, the primary aim of this study was to assess the visual acuity (VA) and the total number of injections needed on average for these patients during the 24-month follow-up. MATERIALS AND METHODS: This is a retrospective observational study from an electronic medical record of consecutive patients treated with intravitreal aflibercept (both naïve and nonnaïve eyes) who had completed the 24-month follow-up since the commencement of treatment. Patients followed the VIEW protocol in year 1 whereas in year 2, an as required approach/Pro Re Nata (PRN) was used. RESULTS: Eighty-seven eyes of 78 patients were analyzed. 43.7% were nonnaive eyes. Baseline VA for all eyes (logMAR) was 52.6 letters, improving to 56.2 letters at 12 months and 55 at 24 months. Almost 83.9% of the treated eyes (81.3% of the patients) did not experience any significant visual loss receiving on average of 9.9 injections in the 24 months of follow-up and attending the hospital eye service 20.3 times in total. CONCLUSIONS: Aflibercept as monotherapy for the treatment of nAMD is associated with good 2nd year outcomes in a real-world setting using the PRN approach in year 2 and fewer injections comparing to the clinical studies, but a higher proportion of follow-up visits compared to the treat and extend regimen.


How to cite this article:
Siempis T, El Abiary M, Patel R, Gupta M. Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration.Oman J Ophthalmol 2019;12:99-103


How to cite this URL:
Siempis T, El Abiary M, Patel R, Gupta M. Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration. Oman J Ophthalmol [serial online] 2019 [cited 2022 Jun 26 ];12:99-103
Available from: https://www.ojoonline.org/article.asp?issn=0974-620X;year=2019;volume=12;issue=2;spage=99;epage=103;aulast=Siempis;type=0